Kura Oncology (KURA) Long-Term Debt Repayments (2018 - 2021)
Kura Oncology (KURA) posted quarterly Long-Term Debt Repayments of $6.5 million for Q2 2021, up 766.67% quarter-over-quarter from $750000.0 in Q1 2021.
Kura Oncology (KURA) Long-Term Debt Repayments (2018 - 2021) Analysis & Trends
Kura Oncology (KURA) has reported Long-Term Debt Repayments for 2 consecutive years, with $6.5 million the latest figure, recorded in Q2 2021.
- In Q2 2021, Long-Term Debt Repayments changed N/A year-over-year to $6.5 million; the TTM figure through Dec 2021 stood at $7.2 million (changed N/A YoY), while the FY2021 annual figure was $7.2 million, up 2800.0% from the prior year.
- Long-Term Debt Repayments grew to $6.5 million in Q2 2021 per KURA's latest filing, from $750000.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $6.5 million in Q2 2021 and bottomed at $250000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 17.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 6.50 Mn |
| Jun 30, 2021 | 6.50 Mn |
| Mar 31, 2021 | 750,000.00 |
| Mar 31, 2021 | 750,000.00 |
| Dec 31, 2018 | 250,000.00 |
| Dec 31, 2018 | 250,000.00 |
| Sep 30, 2018 | 750,000.00 |
| Sep 30, 2018 | 750,000.00 |